Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

TET proteins needed to maintain genome instability, say researchers

Members of the TET (short for ten-eleven translocation) family have been known to function as tumor suppressors for many years, but how they keep a lid on the uncontrolled cell proliferation of cancer cells had remained uncertain. Now, researchers at the La Jolla Institute for Allergy and Immunology demonstrate that TET proteins collectively constitute a major class of tumor suppressors and are required to maintain genome instability.

9 Dec 2015

Study: Older breast cancer patients have better survival rates than what is predicted by ePrognosis tool

Older women with early-stage, invasive breast cancer had better survival rates than what was estimated by a popular online tool for predicting survival, according to researchers at the Duke Cancer Institute.

9 Dec 2015

NeoGenomics introduces NeoLAB Solid Tumor Monitor, NeoLAB BTK Inhibitor Acquired Resistance test

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today an expansion of its liquid biopsy testing menu to include two new tests, a NeoLAB Solid Tumor Monitor and a NeoLAB BTK Inhibitor Acquired Resistance test.

8 Dec 2015

Researchers find new significant link between NPM protein and development of AML

A team of researchers from the National University of Singapore has found a new significant correlation between the protein nucleophosmin (NPM) and the development of an aggressive form of blood cancer called acute myeloid leukemia (AML).

8 Dec 2015

Pediatric chemotherapy regimen improves outcomes in young adults with ALL

Using a pediatric chemotherapy regimen to treat young adults with acute lymphoblastic leukemia (ALL) significantly improved their outcomes compared to what has historically been achieved with 'adult' treatment protocols, report Dana-Farber Cancer Institute scientists.

8 Dec 2015

First targeted treatment to improve survival of high-risk patients with acute myeloid leukemia

Midostaurin added to standard chemotherapy is the first targeted treatment to improve survival of a high-risk, genetically defined subgroup of patients with acute myeloid leukemia (AML), reported Dr. Richard Stone, of Dana-Farber Cancer Institute, on behalf of the Alliance for Clinical Trials in Oncology group, in a plenary session at the 57th American Society of Hematology Annual Meeting and Exposition in Orlando.

8 Dec 2015

Study: Certain characteristics can lead to therapy-related leukemia in breast cancer survivors

A new analysis indicates that certain characteristics may increase a breast cancer survivor’s risk of developing leukemia after undergoing chemotherapy and/or radiation. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings are a first step toward finding ways to prevent this serious and potentially life-threatening treatment-related complication.

8 Dec 2015

Amgen’s Phase 2 data supports safety, efficacy of BLINCYTO in ALL patients with minimal residual disease

Amgen today announced that new data from three Phase 2 trials support the efficacy and safety of BLINCYTO (blinatumomab) in adults with acute lymphoblastic leukemia (ALL).

8 Dec 2015

New approaches to treating leukemia, lymphoma and myeloma

New, highly targeted treatment approaches for leukemia, lymphoma, and myeloma to be presented today at the 57th American Society of Hematology Annual Meeting and Exposition represent a tremendous expansion of oral and intravenous therapy options for patients with blood cancers.

7 Dec 2015

Yale study identifies how myeloma cells escape treatment

One of the biggest questions about the treatment of multiple myeloma, a form of blood cancer, is why nearly all patients treated with current therapies eventually suffer relapse. A Yale Cancer Center study may have solved this mystery by identifying how cancer cells escape treatment, leading to recurrence.

7 Dec 2015

Ibrutinib more effective than traditional chemotherapy in older untreated patients with CLL

A multi-center, international, randomized, Phase III study of older untreated patients with chronic lymphocytic leukemia (CLL) demonstrated that ibrutinib, a kinase inhibitor, is significantly more effective than traditional chemotherapy with chlorambucil.

7 Dec 2015

Prophylactic antibiotics reduce risk of serious bacterial infections in children with ALL

Prophylactic antibiotics significantly reduce the risk of serious bacterial infections in children during the critical first month of treatment for acute lymphoblastic leukemia (ALL), the most common childhood cancer, according to a U.S. and Canadian study led by investigators from Dana-Farber/Boston Children's Cancer and Blood Disorders Center.

7 Dec 2015

Gene therapy shows promise in children with Wiskott-Aldrich syndrome

Researchers reported promising preliminary outcomes for the first four children enrolled in a U.S. gene therapy trial for Wiskott-Aldrich syndrome (WAS), a life-threatening genetic blood and immune disorder, at the 57th annual meeting of the American Society of Hematology (abstract #260).

7 Dec 2015

Research reveals genetic variants linked to treatment-related complications in children with blood diseases

Research to be presented today at the 57th American Society of Hematology Annual Meeting and Exposition reveals genetic variants that are associated with disease severity and treatment-related complications in children with blood diseases.

7 Dec 2015

Genetic variations associated with increased risk for osteonecrosis in young ALL patients

Variations in genes involved in normal bone development are associated with an 8- to 15-fold increased risk for osteonecrosis in young patients with acute lymphoblastic leukemia (ALL), according to research led by St. Jude Children's Research Hospital and Children's Oncology Group investigators.

7 Dec 2015

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

New research adds to a growing body of evidence that gene therapy, an experimental technique that involves correcting or replacing a person's mutated or malfunctioning genes, may improve health outcomes for patients with inherited bleeding and immune disorders as well as some forms of blood cancer.

7 Dec 2015

Study identifies new recurrent genetic mutations involved in origin of AML

Mariam Ibáñez, lecturer at Universidad Cardenal Herrera CEU (CEU Cardenal Herrera University, UCH-CEU) and biologist at "La Fe" Hospital in Valencia used massive sequencing techniques to identify new recurrent genes mutations involved in the origin of acute myelogenous leukemia (AML).

1 Dec 2015

Discovery may lead to potential new therapeutic approach to eradicate blood cancers

An international team of scientists, headed by researchers at UC San Diego School of Medicine and UC San Diego Moores Cancer Center, report that decreases in a specific group of proteins trigger changes in the cancer microenvironment that accelerate growth and development of therapy-resistant cancer stem cells (CSCs).

1 Dec 2015

Researchers discover drug target and genetic pathway for graft-versus-host disease

A Seattle Children's Research Institute lab has discovered a genetic pathway that can be targeted with existing drugs to prevent graft-versus-host disease (GVHD), a common and deadly complication of bone marrow transplants.

30 Nov 2015

Comorbidities relevant to CML TKI choice common

Comorbid conditions that could affect the choice of tyrosine kinase inhibitor are common in patients with chronic myeloid leukaemia, finds an analysis of a US claims database.

27 Nov 2015

Leukemia News and Research

Further Reading

TET proteins needed to maintain genome instability, say researchers

Study: Older breast cancer patients have better survival rates than what is predicted by ePrognosis tool

NeoGenomics introduces NeoLAB Solid Tumor Monitor, NeoLAB BTK Inhibitor Acquired Resistance test

Researchers find new significant link between NPM protein and development of AML

Pediatric chemotherapy regimen improves outcomes in young adults with ALL

First targeted treatment to improve survival of high-risk patients with acute myeloid leukemia

Study: Certain characteristics can lead to therapy-related leukemia in breast cancer survivors

Amgen’s Phase 2 data supports safety, efficacy of BLINCYTO in ALL patients with minimal residual disease

New approaches to treating leukemia, lymphoma and myeloma

Yale study identifies how myeloma cells escape treatment

Ibrutinib more effective than traditional chemotherapy in older untreated patients with CLL

Prophylactic antibiotics reduce risk of serious bacterial infections in children with ALL

Gene therapy shows promise in children with Wiskott-Aldrich syndrome

Research reveals genetic variants linked to treatment-related complications in children with blood diseases

Genetic variations associated with increased risk for osteonecrosis in young ALL patients

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

Study identifies new recurrent genetic mutations involved in origin of AML

Discovery may lead to potential new therapeutic approach to eradicate blood cancers

Researchers discover drug target and genetic pathway for graft-versus-host disease

Comorbidities relevant to CML TKI choice common

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News